Background: Studies on the determination of carnitine levels and nutritional status in patients of type II diabetes. Objective: We designed this study to determine changes of serum-free L-carnitine in type II diabetic women. Design: A cross-sectional study (case-control study). Setting: Clinical of Endocrinology and Metabolism, Sina Hospital, Pharmacological Research Center, Tabriz Medical university, Iran. Patients and methods: Taking into account the importance of the control of diabetes, in the present case-control study, the levels of serum-free L-carnitine, blood glucose and lipids, systolic and diastolic blood pressure, body mass index (BMI) and nutritional status assessed in the case and control groups which were selected by the simple sampling method. The control group (n ¼ 18) included patients with no complications and the case group (n ¼ 33) was grouped into three subgroups including patients with retinopathy, hyperlipidemia and neuropathy. Results: Study results indicated that the mean serum-free L-carnitine concentration in the case group was significantly lower than its mean concentration level in the control group, 39.6378.99 vs 53.4270.93 mmol/l, respectively (Po0.001). Serum-free L-carnitine in retinopathy, hyperlipidemia and neuropathy case subgroups were 39.0379.89, 39.6378.99 and 40.44712.50 mmol/l, respectively (P40.05). No significant difference was found between the serum-free carnitine levels of the case subgroups. The mean blood glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol, very lowdensity lipoprotein cholesterol levels and systolic and diastolic blood pressure were significantly higher in the case group than in the control group. Conclusion: In this study, the mean serum-free L-carnitine levels in diabetic patients with complications was almost 25% lower than in diabetic patients with no complications. On the basis of the study results, carnitine supplementation in diabetic patients, especially in patients with diabetes complications, might be useful.
Introduction
Diabetes mellitus is often accompanied by dyslipidemia and dysfunction in glucose and protein metabolism (Marc et al., 2005) . Type II diabetes is associated with a two-to fourfold excess risk of coronary heart disease (CHD). Although the degree of glycemia in diabetic patients is strongly related to the risk of microvascular complications (retinopathy and renal diseases), the relation of glycemia to macrovascular disease in type II diabetes is more modest (ADA, 2003) . There are studies that have reported abnormal carnitine metabolism in diabetes (Williamson et al., 1992) .
The synthesis of L-carnitine requires two essential amino acids (lysine and methionine), iron (Fe 2 þ ), and vitamins C, B 6 and niacin in the form of nicotinamide dinucleotide (NAD) (Seim et al., 2001) . Carnitine is synthesized primarily in the liver and also in the kidney, and must be transported to other tissues. It is most concentrated in tissues that use fatty acids as their primary dietary fuel, such as skeletal and cardiac (heart) muscle (Arrigoni-Martelli and Caso, 2001) . Carnitine acyltransferases have crucial functions in fatty acid metabolism. Members of this enzyme family show distinctive substrate preferences for short-, medium-or long-chain fatty acids. The molecular mechanism for this substrate selectivity is not clear because so far only the structure of carnitine acetyltransferase has been determined (Gerwald et al., 2005) . Carnitine deficiency may be primary or secondary. In all cases, secondary carnitine deficiencies are characterized by decreased availability of free L-carnitine. In such cases, total carnitine levels may be normal, but free L-carnitine levels are decreased.
Factors such as sex, age, nutritional status, fasting and disease have been cited as influencing plasma carnitine levels in man (Cederblad, 1987) . Plasma carnitine levels have been found to be normal or decreased in studies on carnitine metabolism in diabetes mellitus patients (Okuda et al., 1987; Winter et al., 1987; Pregnant et al., 1993) .
Diabetes in animals and human lead to deterioration of carnitine and lipid metabolism (Depalo et al., 1981; Cederblad et al., 1982; Hoppel and Genuth, 1982; Stearns, 1983; Brooks et al., 1985; Aoshima et al., 1993) . It is well known that streptozotocin-induced diabetic rats develop myocardial carnitine deficiency (Vary and Neely, 1982; Brooks et al., 1985; Aoshima et al., 1993) . In several studies, decreased carnitine concentrations in diabetic animals have been observed (Vary and Neely, 1982; Aoshima et al., 1993) . Acute hypercarnitinemia stimulates nonoxidative glucose disposal during euglycemic hyperinsulinemic clamp in healthy volunteers. Similar results were obtained in type II diabetic patients (Cattolica et al., 2004) . L-carnitine, which is required for mitochondrial free fatty acid (FFA) transport/ oxidation, has been reported to improve vascular function in subjects with diabetes and heart disease (Shankar et al., 2004) . The above studies suggest a relationship between diabetes and FFA and plasma carnitine.
The aim of the present experimental study was to investigate the content of free L-carnitine in type 2 diabetic women with and without complications.
Methods
In the present case -control study, the levels of serum-free L-carnitine, blood glucose and lipids, systolic and diastolic blood pressure, body mass index (BMI) and nutritional factors participating in carnitine biosynthesis (iron, vitamins B 6 , niacin and vitamin C) were determined in 33 diabetic women with complications (case group) and 18 diabetic women without complications (control group) of the same age (30-65 years), who were selected by the simple sampling method.
In this study, patients with CHD, anemia, chronic renal failure, heart failure, liver cirrhosis, antiepileptic drug users and those who receive carnitine treatment were excluded from the study. The patients were grouped into four groups, the control group included the patients with no complications and the case group was divided into three subgroups, patients with retinopathy, hyperlipidemia and polyneuropathy. Diagnosis of retinopathy was carried out by fundoscopic examination of the eye, neuropathy with examination with current methods. All the patients were screened for lipid profile. Serum total cholesterol, highdensity lipoprotein (HDL), triglycerides (TG), low-density lipoprotein (LDL) and glucose concentrations were measured using enzymatic methods.
The sample was transported on dry ice to the laboratory where serum was separated from the cells. Serum was stored at À201C before batch analysis. Free L-carnitine concentration in serum was estimated by using the BoehringerManheim kit. This kit utilizes the enzymatic UV test described by Weiland (1985) .
The results are presented as mean7standard deviation (s.d.). The cutoff level for statistical significance was set at Po0/05. Unpaired Student's t-test (two-tailed) and analysis of variance (ANOVA) test were used to determine differences between independent groups.
Results
According to the study results, increase in age was positively related with increasing BMI. Total dietary fiber consumption was lower than normal levels (25 g/day). Table 1 shows the concentrations of serum glucose and plasma lipids profile. Fasting blood glucose (FBG), TG, total cholesterol, LDL-c and VLDL-c levels were significantly higher in the case group than in the control group (Table 2) .
Study results indicated that the mean serum-free Lcarnitine concentration in the case group was significantly lower than its mean concentration (39.6378.99 vs 53.4270.93 mmol/l, respectively, Po0.001 level) in the control group (Table 3) . Free carnitine (FC) levels of the groups with hyperlipidemia, and polyneuropathy and retinopathy were not significantly different when compared with each other (P40.05) ( Table 3) . Statistical regression analysis test showed a positive significant relationship between serum-free L-carnitine and the percent of protein intake (r ¼ 0.35, P ¼ 0.04), and also the lysine intake (r ¼ 0.34, P ¼ 0.04), in the case group.
Discussion
Carnitine is necessary to maintain normal cardiac function. Decreased levels of carnitine in cardiac tissue may impair myocardial function, as it has been shown that carnitine deficiency can produce cardiomyopathy (Akisu et al., 2002) . It has been thought that there is a relation between insufficient control of metabolism and complications in diabetes (Morabito et al., 1993) . Also, elevated FFA levels diminish glucose-induced insulin secretion by a glucosefatty acid cycle in which fatty acid oxidation inhibits glucose oxidation by decreasing pyruvate dehydrogenase (PDH) activity and increasing PDH kinase activity (Zhou et al., 1996) . It has been thought that carnitine plays an important role in diabetes and its complications (Tamamogullart et al., 1999) . De grandis acetyl-L-carnitine was effective in improving neurophysiological parameters and in reducing pain in patients with diabetic neuropathy. Our study indicated that free L-carnitine concentration in the case group was significantly lower than its mean concentration level in the control group. The mean blood glucose, TG, total cholesterol, LDL-c, VLDL-c levels and systolic and diastolic blood pressure were significantly higher in the case group than in the control group.
In several studies, decreased carnitine concentrations in both plasma and myocardium in diabetic animals have been observed. Inokuchi reported that the combination of impaired glucose tolerance (IGT) with simple obesity may trigger the acceleration of hepatic ketogenosis in conjunction with an elevated SCAC (short-chain acylcarnitine) and an increased AC/FC ratio (acylcarnitine/free carnitine) (Inokuchi et al., 1995) . Susa C found a relation between the levels of urine glucose and ketones and the level of acylcarnitine. They also showed that carnitine deficiency and relative insufficiency may be an overlooked component in the management of diabetes (Winter et al., 1987) . Keller et al. (1998) suggested that acute L-carnitine supplementation significantly improves the recovery of the ischemic myocardium in diabetic and euglycemic rats. The results showed that the total and free carnitine levels are low in diabetes mellitus complications (Tamamogullart et al., 1999) . Irat et al. (2003) suggested that the beneficial effects of L-carnitine treatment partially improve vascular reactivity and antioxidant property beyond its reduction of plasma lipids and it may have an important therapeutic approach in the treatment of diabetic vascular complications.
In our study, the mean serum-free Lcarnitine levels in diabetic patients with complications was almost 25% lower than diabetic patients with no complications.
It could be supposed that this difference might be due to increased carnitine acylation, increased acyl-L-carnitine excretion or its decreased renal reabsorption. This difference may be the result of increased carnitine requirement in diabetic patients with complications also. Steiber et al. (2004) reported that plasma carnitine concentration positively correlates with the dietary intake of carnitine.
This study showed the possible role of protein and lysine in carnitine biosynthesis (in the case group). However, these relationships were not observed in the control group.
No significant relationship was found between serum-free L-carnitine levels and the other factors participating in the carnitine biosynthesis cycle, including methionine, ascorbic acid, niacin, pyrodoxin and iron intakes, in either of the groups.
Also, no significant relationship was observed between serum-free L-carnitine and blood glucose, lipid profile, BMI and systolic and diastolic blood pressure in any of the groups.
On the basis of the study results, carnitine supplementation in diabetic patients, especially in patients with diabetes complications, might be useful. 
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